edoc-vmtest

Items where Author is "Pestalozzi, B."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: Yes
Number of items: 6.

Yes

Matter-Walstra, K. and Achermann, R. and Rapold, R. and Klingbiel, D. and Bordoni, A. and Dehler, S. and Jundt, G. and Konzelmann, I. and Clough-Gorr, K. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2015) Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons : SAKK 89/09. Oncology, 88 (1). pp. 18-27.

Joerger, M. and Matter-Walstra, K. and Früh, M. and Kühnel, U. and Szucs, T. and Pestalozzi, B. and Schwenkglenks, M.. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer : a cost-utility analysis. Annals of Oncology, Vol. 22, H. 3. pp. 567-574.

Hess, V. and Pratsch, S. and Potthast, S. and Lee, L. and Winterhalder, R. and Widmer, L. and Cescato, C. and Lohri, A. and Jost, L. and Stillhart, P. and Pestalozzi, B. and Herrmann, R.. (2010) Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC) : a phase I/II trial. Annals of Oncology, Vol. 21, H. 12. pp. 2390-2395.

Ribi, K. and Koeberle, D. and Schuller, J. C. and Honegger, H. and Roth, A. and Hess, V. and Moosmann, P. and von Moos, R. and Borner, M. and Lombriser, N. and Pestalozzi, B. and Ruhstaller, T.. (2009) Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Vol. 17. pp. 1109-1116.

Borner, M. and Koeberle, D. and Von Moos, R. and Saletti, P. and Rauch, D. and Hess, V. and Trojan, A. and Helbling, D. and Pestalozzi, B. and Caspar, C. and Ruhstaller, T. and Roth, A. and Kappeler, A. and Dietrich, D. and Lanz, D. and Mingrone, W. and Swiss, Group for Clinical Cancer Research and Bern, and Switzerland, . (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer : a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, Vol. 19, H. 7. pp. 1288-1292.

Thürlimann, B. and Bonnefoi, H. and Cameron, D. and Goldhirsch, A. and Herrmann, R. and Monnerat, C. and von Moos, R. and Pagani, O. and Perey, L. and Pestalozzi, B. and Rochlitz, C. and Suter, T.. (2008) Adjuvant therapy of HER2-positive breast cancer with trastuzumab. Senologie, Vol. 5. pp. 1-3.

This list was generated on Mon Dec 23 05:34:04 2024 CET.